

=> s (emulsion? or liposome?) (p) (fenofibrate or fibrate)

117822 EMULSION?
8913 LIPOSOME?
90 FENOFIBRATE
31 FIBRATE

L1 5 (EMULSION? OR LIPOSOME?) (P) (FENOFIBRATE OR FIBRATE)

=> d 1-5

1. 5,700,471, Dec. 23, 1997, Production of fine particle dye or drug preparations; Lutz End, et al., 424/400; 8/526; 34/372; 252/363.5 [IMAGE AVAILABLE]

2. 4,714,789, Dec. 22, 1987, Halo-biphenyl tertiary alcohols useful in therapy in the treatment of atherosclerosis; Henri Cousse, et al., 568/807 [IMAGE AVAILABLE]

3. 4,452,797, Jun. 5, 1984, 3-Aminosydnonimines compounds and their use; Karl Schonafinger, et al., 514/252; 544/58.2, 60, 366, 367 [IMAGE AVAILABLE]

4. 4,332,801, Jun. 1, 1982, 3-Aminosydnonimines, their preparation and use; Karl Schonafinger, et al., 514/227.8; 544/58.7, 60 [IMAGE AVAILABLE]

5. 4,305,939, Dec. 15, 1981, 3-Aminosydnonimines, their preparation and use; Karl Schonafinger, et al., 514/227.8; 544/58.2, 58.7, 60, 367 [IMAGE AVAILABLE]

=> d 1-5 kwic

US PAT NO: 5,700,471 [IMAGE AVAILABLE]

L1: 1 of 5

DETDESC:

DETD(1)

The . . . advantage of reduced costs but also makes it possible for

the first time to produce stable nano-particles, for example of **fenofibrate**, because when solid particles are produced via aqueous dispersions they immediately grow, by Ostwaldt ripening, into larger particles and thus the result of the micronization is nullified. Ostwaldt ripening is not observed with the **emulsions** which are produced briefly as intermediates in this process. It is additionally slowed down by the complete or substantial avoidance. . .

DETDESC:

DETD(2)

However, . . . substances which are not amenable to processing entirely without solvents because their aqueous dispersions agglomerate and therefore cannot be metered. **Fenofibrate** is one example of this. Substances of this type are therefore, according to the invention, not dispersed in water but. . . suspension, and the remainder of the process is carried out as described previously, ie. immediate spray drying of the melt **emulsion** or rapid cooling of the resulting fine-particle **emulsion** and, where appropriate, dehydration and drying of the resulting suspension. The rapid cooling can expediently be achieved by adding cold. . .

DETDESC:

DETD(26)

Production of a micronisate of **fenofibrate** from an **emulsion** with a solids content of 30%

DETDESC:

DETD(32)

The . . . exchanger (6) at 130.degree. C. The temperature of the mixture reached 92.degree. C., which is above the melting point of **fenofibrate** (80.degree. C.). The resulting **emulsion** was discharged through the pressure-limiting valve (8), conveyed through the heated tube (9) directly into the spray tower (10) and. . . of 80.degree. C. This resulted in a free-flowing powder (11) which on dispersion in water afforded a colloidal dispersion of **fenofibrate** with a particle size of 0.66 .mu.m (volume average, determined by laser diffraction).

US PAT NO: 4,714,789 [IMAGE AVAILABLE]

L1: 2 of 5

DETDESC:

DETD(62)

On . . . form of tablets, pills, capsules, or the like, or liquid form, for example, in the form of solutions, suspensions, or **emulsions**. Alternatively, the pharmaceutical preparations may be made available in a form suitable for injection by subjecting the same to conventional . . . g to 1 mg/kg of body weight and which approximate or are somewhat lower than those usual for Clofibrate and/or **Fenofibrate** may be employed. The pharmaceutical compositions of the invention can be used in human or veterinary medicine where indicated, for. . .

US PAT NO: 4,452,797 [IMAGE AVAILABLE]

L1: 3 of 5

SUMMARY:

BSUM(55)

For . . . suitable for enteral or parenteral administration. Appropriate pharmaceutical formulations are, for example, tablets, sugar-coated tablets, pills, capsules, solutions, suspensions or **emulsions** which, in addition to an effective amount of an active compound of formula I or an acid-addition salt thereof, comprise . . . prazosin, clonidine and Rauwolfia alkaloids), agents which lower the level of fatty acid in the blood (such as bezafibrate and **fenofibrate**) and agents for the prophylaxis of thrombosis (such as phenprocoumon).

US PAT NO: 4,332,801 [IMAGE AVAILABLE]

L1: 4 of 5

SUMMARY:

BSUM(60)

For . . . suitable for enteral or parenteral administration. Appropriate pharmaceutical formulations are, for example, tablets, sugar-coated tablets, pills, capsules, solutions, suspensions or **emulsions** which, in addition to an effective amount of an active compound of formula I or an acid-addition salt thereof, comprise . . . prazosin, clonidine and Rauwolfia alkaloids), agents which lower the level of fatty acid in the blood (such as bezafibrate and **fenofibrate**) and agents for the prophylaxis of thrombosis (such as phenprocoumon).

US PAT NO: 4,305,939 [IMAGE AVAILABLE]

L1: 5 of 5

SUMMARY:

BSUM(60)

For . . . suitable for enteral or parenteral administration. Appropriate pharmaceutical formulations are, for example, tablets, sugar-coated tablets, pills, capsules, solutions, suspensions or **emulsions** which, in addition to an effective amount of an active compound of formula I or an acid-addition salt thereof, comprise.

.
prazosin, clonidine and Rauwolfia alkaloids), agents which lower the level of fatty acid in the blood (such as bezafibrate and **fenofibrate**) and agents for the prophylaxis of thrombosis (such as phenprocoumon).

=> s (emulsion? or liposome? and (fenofibrate or fibrate)

UNMATCHED LEFT PARENTHESIS '(EMULSION?'

=> s (emulsion? or liposome?) and (fenofibrate or fibrate)

117822 EMULSION?

8913 LIPOSOME?

90 FENOFIBRATE

31 FIBRATE

L2 55 (EMULSION? OR LIPOSOME?) AND (FENOFIBRATE OR FIBRATE)

=> d 1-55

1. 5,859,051, Jan. 12, 1999, Antidiabetic agents; Alan D. Adams, et al., 514/469, 307, 415, 457; 546/146; 548/469; 549/283, 462 [IMAGE AVAILABLE]

2. 5,856,503, Jan. 5, 1999, Aminoalkyl-substituted benzo-heterocyclic compounds; Johannes Aebi, et al., 548/207; 544/49, 63, 235; 546/149, 150, 152, 165; 548/241; 549/32, 462, 469 [IMAGE AVAILABLE]

3. 5,847,008, Dec. 8, 1998, Method of treating diabetes and related disease states; Thomas W. Doebber, et al., 514/708, 706, 866, 909, 910 [IMAGE AVAILABLE]

4. 5,821,264, Oct. 13, 1998, Tocotrienols and tocotrienol-like compounds and methods for their use; Ronald H. Lane, et al., 514/458; 549/398, 401, 404, 405, 408, 409 [IMAGE AVAILABLE]

5. 5,795,909, Aug. 18, 1998, DHA-pharmaceutical agent conjugates of taxanes; Victor E. Shashoua, et al., 514/449, 549 [IMAGE AVAILABLE]

6. 5,747,528, May 5, 1998, Chroman derivatives as anti-oxidants; Bharat Kakidas Trivedi, 514/456, 233.5; 544/151; 549/407 [IMAGE AVAILABLE]
7. 5,719,197, Feb. 17, 1998, Compositions and methods for topical administration of pharmaceutically active agents; David P. Kanios, et al., 514/772.6; 424/435, 443; 514/781, 782 [IMAGE AVAILABLE]
8. 5,700,471, Dec. 23, 1997, Production of fine particle dye or drug preparations; Lutz End, et al., 424/400; 8/526; 34/372; 252/363.5 [IMAGE AVAILABLE]
9. 5,698,527, Dec. 16, 1997, Steroidal glycosides as antihyperlipidemic agents; Dooseop Kim, 514/26; 536/5 [IMAGE AVAILABLE]
10. 5,679,704, Oct. 21, 1997, Use of 2- (N-(2-aminoethyl)amino) acetic acid derivatives; Karl Schonafinger, et al., 514/438, 397, 401, 408, 439, 461, 564 [IMAGE AVAILABLE]
11. 5,668,117, Sep. 16, 1997, Methods of treating neurological diseases and etiologically related symptomology using carbonyl trapping agents in combination with previously known medicaments; Howard K. Shapiro, 514/55; 436/74, 518; 514/1, 23, 54, 811, 866, 878, 879, 903, 912; 536/1.11, 20 [IMAGE AVAILABLE]
12. 5,658,944, Aug. 19, 1997, Anti-atherosclerotic aryl compounds; James Mood Chapman, Jr., et al., 514/478, 534, 535, 576, 588, 617, 619; 560/34, 39, 43, 61; 562/439, 444, 457, 471; 564/48, 161, 163, 169 [IMAGE AVAILABLE]
13. 5,645,856, Jul. 8, 1997, Delivery systems for hydrophobic drugs; Jonathan Ernest Lacy, et al., 424/455, 456; 514/784, 785, 786, 937, 975 [IMAGE AVAILABLE]
14. 5,591,772, Jan. 7, 1997, Tocotrienols and tocotrienol-like compounds and methods for their use; Ronald H. Lane, et al., 514/458; 549/401, 408 [IMAGE AVAILABLE]
15. 5,554,611, Sep. 10, 1996, Use of coumarin derivatives; Karl Sch

onafinger, et al., 514/228.2, 233.5, 255, 318, 320, 337, 385, 422, 457

[IMAGE AVAILABLE]

16. 5,500,436, Mar. 19, 1996, 2-(N-(2-aminomethyl)amino)acetic acid derivatives to inhibit advanced glycosylation; Karl Schonafinger, et al., 514/397, 401, 408, 438, 439, 461, 564 [IMAGE AVAILABLE]

17. 5,486,531, Jan. 23, 1996, Hydroxymethylfurazancarboxylic acid derivatives; Karl Schonafinger, et al., 514/364, 340; 546/209, 269.1; 548/125 [IMAGE AVAILABLE]

18. 5,466,687, Nov. 14, 1995, Arylidene-1-azacycloalkanes and arylalkyl-1-azacyclo-alkanes, their salts, medicaments containing these compounds and their use, and processes for their preparation; Roland Maier, et al., 514/212, 226.8, 228.8, 326, 372, 374, 385, 399; 540/598, 601, 603; 544/54, 96, 335; 546/209, 210; 548/146, 238, 314.7 [IMAGE AVAILABLE]

19. 5,455,273, Oct. 3, 1995, N,N-disubstituted arylcycloalkylamines, the salts thereof, pharmaceutical compositions containing these compounds and the use thereof and processes for preparing them; Roland Maier, et al., 514/617, 438, 448, 510, 521, 523, 529, 530, 531, 534, 535, 538, 539, 542, 546, 549, 601, 602, 604, 605, 613, 616, 624, 627, 629 [IMAGE AVAILABLE]

20. 5,446,070, Aug. 29, 1995, Compositions and methods for topical administration of pharmaceutically active agents; Juan A. Mantelle, 514/772.6; 424/485, 486, 487, 488; 514/781, 782 [IMAGE AVAILABLE]

21. 5,424,326, Jun. 13, 1995, Phenyl-1,2,5-oxadiazolecarboxamide-2-oxides, their preparation and their use; Karl Schonafinger, et al., 514/364, 252, 256, 340; 540/524; 544/333, 367; 546/209, 269.1; 548/125 [IMAGE AVAILABLE]

22. 5,424,303, Jun. 13, 1995, Substituted aminophosphonate derivatives, process for their preparation and pharmaceutical compositions containing them; Hieu T. Phan, et al., 514/89; 546/22, 24; 548/113, 115, 413; 549/220, 221; 558/166, 168, 169, 190 [IMAGE AVAILABLE]

23. 5,422,373, Jun. 6, 1995, Anti-atherosclerotic aryl compounds; Karl W. Franzmann, 514/598, 467, 507, 596, 622, 824; 549/449; 560/29; 564/48,

52, 170 [IMAGE AVAILABLE]

24. 5,399,569, Mar. 21, 1995, Salts of
3-(cis-2,6-dimethylpiperidino)
sydnone imine; Karl Schonafinger, et al., 514/326, 318; 546/209;
548/125
[IMAGE AVAILABLE]

25. 5,374,640, Dec. 20, 1994,
Pyridyl-1,2,5-oxadiazolecarboxamide-2-
oxides; Karl Schonafinger, et al., 514/340; 546/269.4 [IMAGE
AVAILABLE]

26. 5,360,812, Nov. 1, 1994, Fused 1,2,5-oxadiazole-2-oxides and
their
use; Joachim Brendel, et al., 514/364; 546/116; 548/126 [IMAGE
AVAILABLE]

27. 5,280,119, Jan. 18, 1994, Heterocyclic amine-boranes, and
method of
inhibiting DNA topoisomerase activity and/or combatting
inflammation,
hyperlipidemia, and/or neoplasia using amine-borane compounds;
Bernard F.
Spielvogel, et al., 544/229; 546/13; 548/110, 405 [IMAGE AVAILABLE]

28. 5,221,680, Jun. 22, 1993, Substituted 3-aminosydnones;
Karl
Schonafinger, et al., 514/326, 318; 544/58.2, 60, 138, 367;
546/193, 209;
548/125 [IMAGE AVAILABLE]

29. 5,204,475, Apr. 20, 1993, Substituted 3-aminosydnone imines
and
salts thereof; Karl Schonafinger, et al., 546/210; 548/125; 549/207
[IMAGE AVAILABLE]

30. 5,179,206, Jan. 12, 1993, Substituted 3-aminosydnone imines;
Eckard
Kujath, et al., 546/209 [IMAGE AVAILABLE]

31. 5,167,964, Dec. 1, 1992, Semi-enteric drug delivery systems
and
methods for preparing same; Nouman Muhammad, et al., 424/482,
78.24, 440,
441, 472, 480, 494, 495, 497 [IMAGE AVAILABLE]

32. 5,166,166, Nov. 24, 1992, 3-dicyclohexylaminosydnone imines,
process
for their preparation and their use; Karl Schonafinger, et al.,
514/364;
548/125 [IMAGE AVAILABLE]

33. 5,155,109, Oct. 13, 1992, 3-piperazinosydnone imines, process
for
their preparation and their use; Karl Schonafinger, et al.,
514/252;

544/367 [IMAGE AVAILABLE]

34. 5,128,331, Jul. 7, 1992, Method for lowering plasma lipid levels or blood pressure; Lan Nguyen, et al., 514/101, 107, 824 [IMAGE AVAILABLE]

35. 5,120,732, Jun. 9, 1992, Substituted 3-aminosyndone imines, a process for their preparation and their use; Karl Schonafinger, et al., 514/236.2, 227.8, 255, 319, 325, 326, 364; 544/60, 138, 367; 546/195, 203, 209; 548/125 [IMAGE AVAILABLE]

36. 5,079,244, Jan. 7, 1992, Substituted 3-aminosyndone imines, pharmaceutical compositions containing same, and process for administering same; Eckard Kujath, et al., 514/227.8, 236.2, 252, 326, 364; 544/60, 138, 367; 548/125 [IMAGE AVAILABLE]

37. 5,043,330, Aug. 27, 1991, Phenol substituted gem-diphosphonate derivatives, process for their preparation and pharmaceutical compositions containing them; Lan Nguyen, et al., 514/107; 558/77, 83, 161; 562/19, 21 [IMAGE AVAILABLE]

38. 5,006,540, Apr. 9, 1991, Substituted 3-aminosydnonimines, processes for their preparation and their use; Karl Schonafinger, et al., 514/361; 548/125 [IMAGE AVAILABLE]

39. 4,946,866, Aug. 7, 1990, Use of oxirancarboxylic acids for the treatment of hyperlipemia; Horst Wolf, et al., 514/475, 824 [IMAGE AVAILABLE]

40. 4,937,244, Jun. 26, 1990, Substituted 3-aminosydnonimines, processes for their preparation and their use; Karl Schonafinger, et al., 514/252, 227.8, 236.2, 326, 364; 544/60, 138, 367; 546/209; 548/125 [IMAGE AVAILABLE]

41. 4,937,241, Jun. 26, 1990, N-substituted N-nitrosoaminoacetonitriles, process for their preparation and their use; Karl Schonafinger, et al., 514/227.5; 544/58.1, 58.2 [IMAGE AVAILABLE]

42. 4,888,333, Dec. 19, 1989, Allylmercaptoacetylsydnonimines, processes for their preparation, and their use; Helmut Bohn, et al., 514/212, 227.8, 236.2, 252, 326, 364; 540/524; 544/60, 138, 367; 546/209; 548/125 [IMAGE AVAILABLE]

43. 4,859,703, Aug. 22, 1989, Lipid regulating compositions; Brian R.

Krause, 514/543; 260/DIG.47; 514/537, 563, 571, 627, 824 [IMAGE AVAILABLE]

44. 4,845,091, Jul. 4, 1989, Substituted 3-amino-sydnonimines, their use and pharmaceutical products containing them; Karl Schonafinger, et al., 514/212, 227.8, 236.5, 252, 326, 364; 540/603; 544/58.2, 58.7, 367; 546/210; 548/125 [IMAGE AVAILABLE]

45. 4,719,209, Jan. 12, 1988, Antiatherosclerotic agent compositions; Tadashi Sasaki, et al., 514/223.8 [IMAGE AVAILABLE]

46. 4,714,789, Dec. 22, 1987, Halo-biphenyl tertiary alcohols useful in therapy in the treatment of atherosclerosis; Henri Cousse, et al., 568/807 [IMAGE AVAILABLE]

47. 4,681,891, Jul. 21, 1987, Dihydro-2,6-dimethyl pyridines, formulations and method of use for treating angina pectoris, high blood pressure or disturbances of cerebral or peripheral blood flow; Karl Schonafinger, et al., 514/340, 342; 546/251, 256, 268.7, 269.4, 270.4 [IMAGE AVAILABLE]

48. 4,610,984, Sep. 9, 1986, Substituted piperazin-1-yl-acetic acid amides; Karl Schonafinger, et al., 514/212, 235.8, 255; 544/121, 357, 359, 360, 372, 379, 386 [IMAGE AVAILABLE]

49. 4,558,058, Dec. 10, 1985, Substituted 1,4-dihydropyridines and their use as medicaments; Karl Schonafinger, et al., 514/342, 333, 340; 546/256, 257, 258, 268.4, 268.7, 269.4, 270.4, 271.4, 272.4, 274.1 [IMAGE AVAILABLE]

50. 4,551,454, Nov. 5, 1985, 3-(4-Alkoxy-carbonylpiperazin-1-yl)-sydnonimines, a process for their preparation and use; Karl Schonafinger, et al., 514/252; 544/367 [IMAGE AVAILABLE]

51. 4,452,797, Jun. 5, 1984, 3-Aminosydnonimines compounds and their use; Karl Schonafinger, et al., 514/252; 544/58.2, 60, 366, 367 [IMAGE AVAILABLE]

52. 4,436,743, Mar. 13, 1984, 3-[N-(Lower alkyl)-N-(tetrahydro-3-thienyl 5,5-dioxide)]sydnonimines; Karl Schonafinger, et al., 514/364, 252; 544/367; 548/125 [IMAGE AVAILABLE]

53. 4,356,178, Oct. 26, 1982, 3,4-(Bis-substituted)-1,2,5-oxdiazole

2-oxides, their use and pharmaceutical formulations containing them; Karl

Schonafinger, et al., 514/212, 232.2, 316, 326, 364; 540/603; 544/82, 138, 357, 367; 546/187, 209; 548/125 [IMAGE AVAILABLE]

54. 4,332,801, Jun. 1, 1982, 3-Aminosydnonimines, their preparation and use; Karl Schonafinger, et al., 514/227.8; 544/58.7, 60 [IMAGE AVAILABLE]

55. 4,305,939, Dec. 15, 1981, 3-Aminosydnonimines, their preparation and use; Karl Schonafinger, et al., 514/227.8; 544/58.2, 58.7, 60, 367 [IMAGE AVAILABLE]

10

file epo

FILE 'EPO' ENTERED AT 10:25:54 ON 08 APR 1999

```
* * * * *
*               G P I
*   E U R O P E A N   P A T E N T   A B S T R A C T S
* * * * *
```

=> s (emulsion? or liposome?) and (fenofibrate or fibrate)

```
18282 EMULSION?
1263 LIPOSOME?
13 FENOFIBRATE
3 FIBRATE
L3      0 (EMULSION? OR LIPOSOME?) AND (FENOFIBRATE OR
FIBRATE)
```

=> file jop

'JOP' IS NOT A VALID FILE NAME
SESSION CONTINUES IN FILE 'EPO'

=> file jpo

FILE 'JPO' ENTERED AT 10:26:44 ON 08 APR 1999

```
* * * * *
*               G P I
*   J A P A N E S E   P A T E N T   A B S T R A C T S
*
*   THE FILE IS CURRENT THROUGH DECEMBER 31, 1998.
* * * * *
```

=> s (emulsion? or liposome?) and (fenofibrate or fibrate)

```
33497 EMULSION?
697 LIPOSOME?
1 FENOFIBRATE
4 FIBRATE
L4      0 (EMULSION? OR LIPOSOME?) AND (FENOFIBRATE OR
FIBRATE)
```